GLIOMATCH is a Horizon Europe project dedicated to pioneering targeted treatments for brain cancer. Led by KU Leuven, the project brings together more than a dozen partners from ten EU member states to advance personalised medicine for one of the most lethal cancer types. In line with Europe’s Beating Cancer Plan, GLIOMATCH contributes to the EU Cancer Mission’s objectives through the ‘Understanding (Tumour-Host) Interactions’ Cluster. By making technology for customised treatments accessible to clinicians, GLIOMATCH aims to relieve the burden brain tumours place on patients, families, and healthcare systems across Europe.
Find out more about the GLIOMATCH project by watching our explainer video. In the video, Prof. Frederik De Smet (KUL), GLIOMATCH project coordinator, breaks down the project’s objectives, innovation, and overall structure.
A first cluster-wide newsletter presents the latest scientific developments, publications, project meetings and activities over the past months across U-THI Cluster projects ARTURO, GLIOMATCH, HIT-GLIO, MULTIR, SPACETIME and THRIVE. It highlights the Cluster’s interdisciplinary strengths and different approaches to patient-centred cancer research.
GLIOMATCH coordinator Prof. Frederik De Smet presented how the project connects tumour tissue, imaging and clinical data to understand responses to immunotherapy and support precision oncology for patients with brain tumours.
In this episode of the GLIOMATCH: Explained video series, Dr. Kathrin Cresswell, Professor of Digital Innovations in Health and Care at the University of Edinburgh, explains how GLIOMATCH is working to ensure the successful use and implementation of its novel data platform. We’ve summarised the interview in this news piece.
